Zydus Lifesciences Share Price
Zydus Lifesciences Share Price Today
As of 25 Jul 2026, Zydus Lifesciences share price is ₹1,111.80. The stock opened at ₹1,109.00, compared to its previous close of ₹1,113.80. During today's trading session, Zydus Lifesciences share price moved in the range of ₹1,099.00 to ₹1,119.60, with an average price of ₹1,109.30 for the day. Looking at its last 52-week, the stock has touched a low of ₹835.50 and a high of ₹1,181.50. On the performance front, Zydus Lifesciences share price has increased by 25.70% over the last six months and is up 14.15% on a year-on-year basis.
Zydus Lifesciences Returns Calculator
Zydus Lifesciences Shareholder Returns
Zydus Lifesciences Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,65,711.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,93,860.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,92,687.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,12,593.00 | 33.55 | 3.27 | 11.27% | 0.00 | 14.95% | 423.36 | 0.92% | 0.45 | 43.52 |
| Lupin | 1,09,553.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,03,472.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 96,204.70 | 30.22 | 2.53 | 11.07% | 0.18 | 12.54% | 377.96 | 0.69% | 0.41 | 38.68 |
| Aurobindo Pharma | 88,508.40 | 25.27 | 2.34 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 84,727.30 | 60.26 | 10.10 | 18.21% | 0.40 | 16.70% | 97.21 | 0.12% | 0.64 | 13.72 |
| Biocon | 70,908.00 | 151.62 | 1.71 | 1.34% | 0.10 | 3.76% | 2.16 | 0.14% | 0.09 | 0.27 |
Zydus Lifesciences Financials
Income Statement · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹27,148.40 | ₹23,241.50 | ₹19,547.40 | ₹17,237.40 |
| Other Income | ₹509.50 | ₹269.50 | ₹284.10 | ₹186.60 |
| Total Revenue | ₹27,657.90 | ₹23,511.00 | ₹19,831.50 | ₹17,424.00 |
| Total Expenses | ₹20,520.20 | ₹17,264.70 | ₹15,008.40 | ₹14,230.10 |
| Profit Before Tax | ₹6,621.10 | ₹6,026.70 | ₹4,808.90 | ₹2,589.70 |
| Tax | ₹1,594.70 | ₹1,411.90 | ₹977.50 | ₹587.80 |
| Profit After Tax | ₹5,026.40 | ₹4,614.80 | ₹3,831.40 | ₹2,001.90 |
| EPS - Basic | ₹50.09 | ₹44.97 | ₹38.14 | ₹19.30 |
| EPS - Diluted | ₹50.09 | ₹44.97 | ₹38.14 | ₹19.30 |
Cash Flow · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹6,621.10 | ₹6,026.70 | ₹4,838.10 | ₹2,582.70 |
| Income before WC changes | ₹6,331.30 | ₹7,047.10 | ₹5,384.80 | ₹3,516.60 |
| Change in Assets | -₹1,732.30 | ₹926.20 | -₹893.40 | -₹261.90 |
| Change in Liabilities | -₹891.40 | ₹609.70 | ₹22.30 | ₹26.10 |
| Change in WC | -₹2,623.70 | ₹1,535.90 | -₹871.10 | -₹235.80 |
| Cash flow from Operations | ₹2,116.60 | ₹6,781.10 | ₹3,227.90 | ₹2,688.80 |
| Cash flow from Investing | -₹8,296.10 | -₹8,357.80 | -₹1,475.20 | ₹1,171.20 |
| Cash flow from Financing | ₹5,806.90 | ₹1,995.30 | -₹1,810.40 | -₹4,400.40 |
| Total Cash Flow | -₹372.60 | ₹418.60 | -₹57.70 | -₹540.40 |
| Cash (Start of the year) | ₹826.80 | ₹413.00 | ₹487.80 | ₹1,106.90 |
| Cash (End of the year) | ₹855.20 | ₹826.80 | ₹413.00 | ₹573.10 |
Balance Sheet · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹32,500.50 | ₹20,155.60 | ₹17,861.00 | ₹15,748.20 |
| Current Assets | ₹19,906.10 | ₹17,046.10 | ₹11,419.80 | ₹10,008.20 |
| Total Assets | ₹52,406.60 | ₹37,201.70 | ₹29,280.80 | ₹25,756.40 |
| Current Liabilities | ₹15,711.90 | ₹9,041.60 | ₹5,339.70 | ₹5,526.70 |
| Net Current Asset | ₹4,194.20 | ₹8,004.50 | ₹6,080.10 | ₹4,481.50 |
| Non-Current Liabilities | ₹7,112.50 | ₹1,801.70 | ₹1,839.50 | ₹541.40 |
| Equity Capital | ₹29,582.20 | ₹26,358.40 | ₹22,101.60 | ₹19,688.30 |
| Total Equity & Liabilities | ₹52,406.60 | ₹37,201.70 | ₹29,280.80 | ₹25,756.40 |
Income Statement · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹11,484.00 | ₹15,116.30 | ₹10,818.70 | ₹8,731.60 |
| Other Income | ₹1,667.50 | ₹696.20 | ₹1,084.80 | ₹548.40 |
| Total Revenue | ₹13,151.50 | ₹15,812.50 | ₹11,903.50 | ₹9,280.00 |
| Total Expenses | ₹8,602.70 | ₹8,367.80 | ₹7,655.10 | ₹7,044.00 |
| Profit Before Tax | ₹4,381.90 | ₹7,444.70 | ₹4,239.80 | ₹2,032.20 |
| Tax | ₹822.10 | ₹1,669.80 | ₹798.30 | ₹503.00 |
| Profit After Tax | ₹3,559.80 | ₹5,774.90 | ₹3,441.50 | ₹1,529.20 |
| EPS - Basic | ₹35.38 | ₹57.39 | ₹34.01 | ₹15.06 |
| EPS - Diluted | ₹35.38 | ₹57.39 | ₹34.01 | ₹15.06 |
Cash Flow · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹4,381.90 | ₹7,444.70 | ₹4,239.80 | ₹2,032.20 |
| Income before WC changes | ₹3,096.50 | ₹7,769.80 | ₹4,090.80 | ₹2,507.30 |
| Change in Assets | ₹10.10 | -₹3,467.20 | -₹1,272.50 | -₹1,070.60 |
| Change in Liabilities | ₹173.60 | ₹159.50 | ₹79.70 | ₹34.70 |
| Change in WC | ₹183.70 | -₹3,307.70 | -₹1,192.80 | -₹1,035.90 |
| Cash flow from Operations | ₹2,234.30 | ₹3,114.00 | ₹2,000.30 | ₹1,078.20 |
| Cash flow from Investing | ₹569.60 | -₹4,503.60 | -₹1,831.80 | -₹1,959.30 |
| Cash flow from Financing | -₹2,579.90 | ₹1,384.50 | -₹300.80 | ₹827.00 |
| Total Cash Flow | ₹224.00 | -₹5.10 | -₹132.30 | -₹54.10 |
| Cash (Start of the year) | ₹103.00 | ₹108.10 | ₹240.40 | ₹294.50 |
| Cash (End of the year) | ₹327.00 | ₹103.00 | ₹108.10 | ₹240.40 |
Balance Sheet · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹17,627.80 | ₹17,002.20 | ₹16,173.50 | ₹13,405.40 |
| Current Assets | ₹16,251.80 | ₹15,314.70 | ₹7,911.30 | ₹7,158.20 |
| Total Assets | ₹33,879.60 | ₹32,316.90 | ₹24,084.80 | ₹20,563.60 |
| Current Liabilities | ₹5,592.60 | ₹7,851.40 | ₹2,541.40 | ₹2,790.10 |
| Net Current Asset | ₹10,659.20 | ₹7,463.30 | ₹5,369.90 | ₹4,368.10 |
| Non-Current Liabilities | ₹4,615.30 | ₹3,275.40 | ₹5,826.90 | ₹4,134.10 |
| Equity Capital | ₹23,671.70 | ₹21,190.10 | ₹15,716.50 | ₹13,639.40 |
| Total Equity & Liabilities | ₹33,879.60 | ₹32,316.90 | ₹24,084.80 | ₹20,563.60 |
About Zydus Lifesciences
Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.
Zydus Lifesciences Financial Highlights
- Revenue: Zydus Lifesciences reported revenue of ₹27,657.90 crore in FY26 vs ₹23,511.00 crore in FY25. It showed an increase of 17.64% on a yearly basis.
- Operating Profit: Zydus Lifesciences reported an operating profit of ₹6,621.10 crore in FY26 vs ₹6,026.70 crore in FY25. It showed an increase of 9.86% on a year-on-year basis.
- Net Profit: Zydus Lifesciences reported a net profit of ₹5,026.40 crore in FY26 vs ₹4,614.80 crore in FY25. It showed an increase of 8.92% on a yearly basis.
Zydus Lifesciences Quarterly Result Highlights
- Zydus Lifesciences reported revenue of ₹7,721.20 crore in Mar 2026, compared with ₹6,975.90 crore in Dec 2025, representing an increase of 10.68% on a quarter-on-quarter (QoQ) basis.
- Zydus Lifesciences reported an operating profit of ₹1,659.70 crore in Mar 2026, compared with ₹1,353.40 crore in Dec 2025, representing an increase of 22.63% on a quarter-on-quarter (QoQ) basis.
- Zydus Lifesciences reported a profit of ₹1,341.30 crore in Mar 2026, compared with ₹965.10 crore in Dec 2025, reflecting an increase of 38.98% on a QoQ basis.
- The earnings per share (EPS) of Zydus Lifesciences stood at ₹50.09 during Mar 2026.
Similar Stocks
FAQs on Zydus Lifesciences Share Price
What is Zydus Lifesciences share price today?
Zydus Lifesciences share price is ₹1,111.80 as on 24 Jul, 2026, 15:29 IST.
How has the Zydus Lifesciences share price performed in the past?
In the last 1 year, Zydus Lifesciences delivered a return of 14.15%. The Zydus Lifesciences share price hit a high of ₹1,181.50 and low of ₹835.50.
How much is the Mutual Fund shareholding in Zydus Lifesciences shares?
The Mutual Fund Shareholding in Zydus Lifesciences was 5.12% at the end of Jun 2026.
What is the the 52-week high and low of Zydus Lifesciences shares ?
The 52-week high and low of Zydus Lifesciences share is ₹1,181.50 and ₹835.50 as of 24 Jul, 2026.
What is the market cap of Zydus Lifesciences?
The market capitalisation of Zydus Lifesciences is ₹1,11,082.00 Crores as on 24 Jul, 2026.
What are the stock symbols of Zydus Lifesciences?
The stock symbol of Zydus Lifesciences is ZYDUSLIFE on the NSE, 532321 on the BSE, and the ISIN is INE010B01027.
What was yesterday's closing price of Zydus Lifesciences shares ?
Zydus Lifesciences shares closed yesterday at ₹1,113.80 on NSE & ₹1,113.60 on BSE
How to buy Zydus Lifesciences shares?
To buy Zydus Lifesciences shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Zydus Lifesciences shares on Holidays?
No, shares of Zydus Lifesciences or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Zydus Lifesciences shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Zydus Lifesciences?
The PE and PB ratio of Zydus Lifesciences is 17.39 and 3.23 respectively, as on 24 Jul, 2026, 15:29 IST.





